(1R,2R)-N-(1-Cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): A Potent and Highly Selective Cathepsin K Inhibitor for the Treatment of Osteoarthritis-Reference-Cited by-同舟云学术

(1R,2R)-N-(1-Cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): A Potent and Highly Selective Cathepsin K Inhibitor for the Treatment of Osteoarthritis

Published:2012-07-10 Issue:14 Volume:55 Page:6363-6374
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Dossetter Alexander G.¹,Beeley Howard¹,Bowyer Jonathan¹,Cook Calum R.¹,Crawford James J.¹,Finlayson Jonathan E.¹,Heron Nicola M.¹,Heyes Christine¹,Highton Adrian J.¹,Hudson Julian A.¹,Jestel Anja²,Kenny Peter W.¹,Krapp Stephan²,Martin Scott¹,MacFaul Philip A.¹,McGuire Thomas M.¹,Gutierrez Pablo Morentin¹,Morley Andrew D.¹,Morris Jeffrey J.¹,Page Ken M.¹,Ribeiro Lyn Rosenbrier¹,Sawney Helen¹,Steinbacher Stefan²,Smith Caroline¹,Vickers Madeleine¹

Affiliation:

1. AstraZeneca R&D, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, U.K.

2. Proteros Biostructures, Am Klopferspitz 19, D-82152 Martinsried, Germany

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm3007257

Reference47 articles.

1. Osteoarthritis

2. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II